April 24th 2024
During a Case-Based Roundtable® event, Misako Nagasaka, MD, discussed treatment for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Discussing Data on Efficacy and Adverse Events of Mobocertinib for NSCLC
December 5th 2022During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, PhD, discussed with participants the adverse event management and expected efficacy of mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion. This is the second of 2 articles based on this event.
Read More
Nadler Reviews Targeted Therapy for EGFR Exon 20 Insertion NSCLC
November 21st 2022During a Targeted Oncology case-based roundtable event, Eric S. Nadler, MD, MPP, discussed the data supporting the use of targeted therapy for patients with non–small cell lung cancer and an EGFR exon 20 insertion.
Read More
Roundtable Discussion: Salgia Looks at Testing and Treatment for NSCLC With EGFR Exon 20 Insertions
November 8th 2022During a Targeted Oncology case-based roundtable event, Ravi Salgia, MD, PhD, discussed with participants their approach to molecular testing and treatment of a patient diagnosed with non–small cell lung cancer.
Read More
Roundtable Discussion: Genetic Testing and Treatment in NSCLC With EGFR 19 Exon Deletion
October 13th 2022During a Targeted Oncology case-based roundtable event, Rachel E. Sanborn, MD, discussed with participants the case of a patient with metastatic lung adenocarcinoma with potential targetable biomarkers.
Read More
Roundtable Discussion: Neal Discusses Molecular Testing and Treatment for EGFR Exon 20+ Lung Cancer
October 6th 2022During a case-based roundtable event, Joel W. Neal, MD, PhD of Stanford Cancer Institute and a group of peers discussed using molecular testing to detect an EGFR exon 20 insertion in a patient with lung cancer.
Read More
Latest Recommendations for Broad Molecular Testing in Advanced NSCLC
September 14th 2022During a live virtual event, Zofia Piotrowska, MD, MHS, discussed the National Comprehensive Cancer Network guidelines for molecular testing for a patient with advanced non–small cell lung cancer, and how to approach a patient who is found to have an EGFR exon 20 insertion. This is the first of 2 articles based on this event.
Read More
Sintilimab Plus Chemotherapy Elicits PFS Benefit in EGFR-mutated Non-Squamous NSCLC
September 8th 2022Findings from the phase 3 ORIENT-31 study shows improved progression-free survival with sintilimab with or without bevacizumab biosimilar injection and chemotherapy in EGFR-mutated non-squamous non-small cell lung-cancer.
Read More
Results of Amivantamab and Mobocertinib Trials Evaluated for Use in NSCLC
August 3rd 2022During a Targeted Oncology case-based roundtable event, Christine Bestvina, MD, discussed the outcomes of clinical trials of the EGFR exon 20-targeted agents amivantamab and mobocertinib with participants. This is the second of 2 articles based on this event.
Read More
Brain Metastasis in Patients With NSCLC Correlates With Enrichment of CDKN2A/B and EGFR Mutations
June 6th 2022Correlations between non–small cell lung cancer the metastasizes to the brain and enriched CDKN2A/B and EGFR alterations calls for further genomic exploration of this patient population.
Read More
NSCLC With Baseline Brain Metastases Predictive of Limited Benefit from Mobocertinib
June 6th 2022In patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer that has progressed after mobocertinib treatment, remaining on mobocertinib may be warranted, according to news research.
Read More